Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07535359) titled 'Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer' on April 9.

Study Type: Expanded Access

Primary Sponsor: Daiichi Sankyo

Condition: SCLC Extensive-stage Small Cell Lung Cancer

Intervention: Drug: Ifinatamab Deruxtecan

Recruitment Status: Not recruiting

Date of First Enrollment: August 2026

To know more, visit https://clinicaltrials.gov/study/NCT07535359

Published by HT Digital Content Services with permission from Health Daily Digest....